Cancer Immunology Community Seeks Better End Points
November 29, 2016
Drug developers are still hunting for surrogate end points that can better capture the benefits of checkpoint inhibitors, oncolytic viruses and modified T cell therapies.
Continue reading here.
A closer listen to lion calls may help map where the big cat is under threat.
Scientists remain split on whether rope-pulling ingenuity counts as tool use.